Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 18, 2025

CD159c (NKG2C) Antibody, anti-human, pure, REAfinity™

RRID:AB_2801859 Type: Antibody

Proper Citation

(Miltenyi Biotec Cat# 130-122-278, RRID:AB_2801859)

Antibody Information

URL: http://antibodyregistry.org/AB_2801859

Proper Citation: (Miltenyi Biotec Cat# 130-122-278, RRID:AB_2801859)

Target Antigen: CD159c (NKG2C)

Host Organism: human

Clonality: monoclonal

Antibody Name: CD159c (NKG2C) Antibody, anti-human, pure, REAfinity™

Description: This monoclonal targets CD159c (NKG2C)

Target Organism: human

Clone ID: clone REA205

Antibody ID: AB_2801859

Vendor: Miltenyi Biotec

Catalog Number: 130-122-278

Record Creation Time: 20241106T181445+0000

Record Last Update: 20241109T061428+0000

Ratings and Alerts

No rating or validation information has been found for CD159c (NKG2C) Antibody, antihuman, pure, REAfinity™.

No alerts have been found for CD159c (NKG2C) Antibody, anti-human, pure, REAfinity™.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. Cell, 187(11), 2817.

Rosain J, et al. (2023) Human IRF1 governs macrophagic IFN-? immunity to mycobacteria. Cell, 186(3), 621.

Salomé B, et al. (2022) NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer cell, 40(9), 1027.